Manuscript | Flatiron Health

D'Amico, TA, Bandini, L, Balch, A, Benson III, AI, Edge, SB, Fitzgerald, L, Green, RJ, Koh, W, Kolodziej, MA, Kumar, S, Meropol, NJ, Mohler, JL, Pfister, D, Walters, RS, Carlson, RW

March 2020

Manuscript

JNCCN

Flatiron-authored

Author’s response to ‘‘A Letter in Support of Real-World RECIST’’ →

Griffith, SD, Tucker, MG, Bowser, B, Calkins, G, Chang, C, Guardino, E, Khozin, S, Kraut, J, You, P, Schrag, D, Miksad, RA

February 2020

Manuscript

Advances in Therapy

Flatiron-authored

Real-world dosing patterns and outcomes of patients with metastatic pancreatic cancer treated with a liposomal irinotecan regimen in the United States →

Barzi, A, Miksad, RA, Surinach, A, Corvino, FA, Wang, S, Torres, AZ, Mamlouk, K, Pulgar, S, Valderrama, A, Bekaii-Saab, T, Ahn, D

January 2020

Manuscript

Pancreas

Flatiron-authored

Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma →

Moser, JC, Wei, G, Colonna, SV, Grossman, KF, Patel, SB, Hyngstrom, JR

January 2020

Manuscript

Acta Oncologia

Prognostic significance of cancer patient reported outcomes in cancer →

Kerrigan, KC, Patel, SB, Halland, B, Ose, D, Chalmers, AW, Haydell, T, Meropol, NJ, Akerley, WL

January 2020

Manuscript

Journal of Oncology Practice

Flatiron-authored

Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States →

George, DJ, Sartor, AO, Miller, K, Saad, F, Tombal, B, Kalinovsky, J, Jiao, X, Tangirala, K, Sternberg, CN, Higano, CS

January 2020

Manuscript

Clinical Genitourinary Cancer

First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis →

Parikh, RB, Feld, EK, Galsky, MD, Adamson, BJS, Cohen, AB, Baxi, SS, Boursi, SB, Christodouleas, JP, Vaughn, DJ, Meropol, NJ, Mamtani, R

December 2019

Manuscript

Future Oncology

Flatiron-authored

Challenges and opportunities to updating prescribing information for longstanding oncology drugs →

Balogh, EP, Bindman, AB, Eckhardt, SG, Halabi, S, Harvey, RD, Jaiyesimi, I, Miksad, RA, Moses, HL, Nass, SJ, Schilsky, RL, Sun, S, Torrente, JM, Warren, KE

December 2019

Manuscript

The Oncologist

Flatiron-authored

Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with frontline BRAF/MEK inhibitors, anti-PD-1, or nivolumab/ipilimumab →

Moser, JC, Chen, D, Hu-Lieskoven, S, Grossman, KF, Patel, SB, Colonna, SV, Ying, J, Hyngstrom, JR

November 2019

Manuscript

Cancer Medicine

Technology-enabled clinical trials: Transforming medical evidence generation →

Marquis-Gravel, G, Roe, MT, Turakhia, MP, Boden, W, Temple, R, Sharma, A, Hirshberg, B, Slater, P, Craft, N, Stockbridge, N, McDowell, B, Waldstreicher, J, Bourla, AB, Bansilal, S, Wong, JL, Meunier, C, Kassahun, H, Coran, P, Bataille, L, Patrick-Lake, B, Hirsch, BR, Reites, J, Mehta, R, Muse, ED, Chandross, KJ, Silverstein, JC, Silcox, C, Overhage, JM, Califf, RM, Peterson, ED

October 2019

Manuscript

Circulation

Flatiron-authored

Association between FDA label restriction and immunotherapy and chemotherapy use in bladder cancer →

Parikh RB, Adamson BJS, Khozin S, Galsky MD, Baxi SS, Cohen A, Mamtani R

September 2019

Manuscript

JAMA

Flatiron-authored

Real-world treatment patterns and clinical outcomes across lines of therapy in patients with advanced/metastatic gastric or gastroesophageal junction cancer →

Le, DT, Ott, PA, Korytowsky, B, Le, H, Le, TK, Zhang, Y, Maglinte, GA, Abraham, P, Patel, D, Shangguan, T, Chau, I

September 2019

Manuscript

Clinical Colorectal Cancer

Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer →

Chau I, Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Sanchez T, Maglinte GA, Laurie M, Abraham P, Patel D, Shangguan T

September 2019

Manuscript

Gastric Cancer

Cost effectiveness of PD-L1-based test-and-treat strategy with pembrolizumab as the first-line treatment for metastatic NSCLC in Hong Kong →

Loong HH, Wong CKH, Leung LKS, Dhankhar P, Insinga RP, Chandwani S, Hsu DC, Lee MYK, Huang M, Pellissier J, Rai A, Achra M, Tan SC

September 2019

Manuscript

Pharmacoeconomics Open

Real-world clinical and economic outcomes and the role of bevacizumab in non-small cell lung cancer patients with liver metastases →

Wong, WB, Wu, N, Yang, E, Davies, J, Chae, YK

September 2019

Manuscript

Journal of Oncology Practice

Validation of diagnosis codes to identify side of colon in an electronic health record registry →

Luhn P, Kuk D, Carrigan G, Nussbaum N, Sorg R, Rohrer R, Tucker MG, Arnieri B, Taylor MD, Meropol NJ

August 2019

Manuscript

BMC Medical Research Methodology

Flatiron-authored

Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non–small-cell lung cancer data set →

Griffith SD, Miksad RA, Calkins G, You P, Lipitz NG, Bourla AB, Williams E, George DJ, Schrag D, Khozin S, Capra WB, Taylor MD, Abernethy AP

August 2019

Manuscript

JCO Clinical Cancer Informatics

Flatiron-authored

Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer →

Luhn P, Chui SY, Hsieh AF, Yi J, Mecke A, Bajaj PS, Hasnain W, Falgas A, Ton TG, Kurian AW

August 2019

Manuscript

Journal of Comparative Effectiveness Research

Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer →

Khozin S, Miksad RA, Adami J, Boyd M, Brown NR, Gossai A, Kaganman I, Kuk D, Rockland JM, Pazdur R, Torres AZ, Zhi J, Abernethy AP

August 2019

Manuscript

Cancer

Flatiron-authored

Survival of patients with metastatic HER2 positive gastroesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on frontline chemotherapy plus trastuzumab →

Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I

July 2019

Manuscript

Journal of Clinical Oncology

Effectiveness of first-line immune checkpoint blockade versus carboplatin-based chemotherapy for metastatic urothelial cancer →

Feld E, Harton J, Meropol NJ, Adamson BJS, Cohen A, Parikh RB, Galsky MD, Narayan V, Christodouleas J, Vaughn DJ, Hubbard RA, Mamtani R

July 2019

Manuscript

European Urology

Flatiron-authored

Using Electronic Health Records to Derive Control Arms for Early Phase Single‐Arm Lung Cancer Trials: Proof‐of‐Concept in Randomized Controlled Trials →

Carrigan G, Whipple S, Capra WB, Taylor MD, Brown JS, Lu M, Arnieri B, Copping R, Rothman KJ

July 2019

Manuscript

Clinical Pharmacology and Therapeutics

An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non-small-cell lung cancer →

Stewart M, Norden AD, Dreyer N, Henk HJ, Abernethy AP, Chrischilles E, Kushi L, Mansfield AS, Khozin S, Sharon E, Arunajadai S, Carnahan R, Christian JB, Miksad RA, Sakoda LC, Torres AZ, Valice E, Allen J

July 2019

Manuscript

JCO Clinical Cancer Informatics

Flatiron-authored

Real-world experience with pembrolizumab in patients with advanced melanoma →

Liu FX, Ou W, Diede SJ, Whitman ED

July 2019

Manuscript

Medicine

Cost effectiveness of multigene panel sequencing for patients with advanced non–small-cell lung cancer →

Steuten, L, Goulart, B, Meropol, NJ, Pritchard, D, Ramsey, SD

June 2019

Manuscript

JCO Clinical Cancer Informatics

Flatiron-authored

ISPOR, the FDA, and the evolving regulatory science of medical device products →

O'Neill T, Miksad R, Miller D, Maloney L, John A, Hiller C, Hornberger, J

June 2019

Manuscript

Value in Health

Flatiron-authored

First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: Real-world analysis of time on treatment →

Velcheti V, Chandwani S, Chen X, Pietanza MC, Burke T

June 2019

Manuscript

Immunotherapy

Generating real-world tumor burden endpoints from electronic health record data: Comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer →

Griffith S, Tucker M, Bowser B, Calkins G, Chang C-H, Guardino E, Khozin S, Kraut J, You P, Schrag D, Miksad RA

May 2019

Manuscript

Advances in Therapy

Flatiron-authored

Comparative effectiveness of carboplatin/pemetrexed with versus without bevacizumab for advanced nonsquamous non-small cell lung cancer →

Bagley SJ, Talento S, Mitra N, Meropol NJ, Cohen RB, Laner CJ, Vachani A

May 2019

Manuscript

JNCCN

Flatiron-authored

Small But Mighty: The Use of Real‐World Evidence to Inform Precision Medicine →

Miksad RA, Samant MK, Sarkar S, Abernethy AP

May 2019

Manuscript

Clinical Pharmacology and Therapeutics

Flatiron-authored

Real-world outcomes and factors associated with the second-line treatment of patients with gastric, gastroesophageal junction, or esophageal adenocarcinoma →

Barzi A, Hess LM, Zhu YE, Liepa AM, Sugihara T, Beyrer J, Chao J

May 2019

Manuscript

Cancer Control

Real-world clinical impact of immune checkpoint inhibitors in patients with advanced/metastatic non-small cell lung cancer after platinum chemotherapy →

Schwartzberg L, Korytowsky B, Penrod JR, Zhang Y, Le TK, Batenchuk C, Krug L

April 2019

Manuscript

Clinical Lung Cancer

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database →

Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, Gossai A, Frampton GM, Torres AZ, Lehnert E, Bourque D, O’Connell C, Bowser B, Caron T, Baydur E, Seidl-Rathkopf K, Ivanov I, Alpha-Cobb G, Guria A, He J, Frank S, Nunnally A, Bailey M, Jaskiw A, Feuchtbaum D, Nussbaum N, Abernethy AP, Miller VA.

April 2019

Manuscript

JAMA

Flatiron-authored

Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US setting →

Simeone JC, Nordstrom, BL, Ketan P, Mann H, Klein AB, Horne L.

April 2019

Manuscript

Cancer Epidemiology

Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice →

Parikh RB, Galsky MD, Gyawali B, Riaz F, Kaufmann T, Cohen AB, Adamson BJS, Gross CP, Meropol NJ, Mamtani R.

April 2019

Manuscript

The Oncologist

Flatiron-authored

Challenges of using ICD-9-CM and ICD-10-CM codes for soft-tissue sarcoma in databases for health services research →

Hess LM, Zhu YE, Sugihara T, Fang Y, Collins N, Nicol S

April 2019

Manuscript

Perspectives in Health Information Management

Implementing an Electronic End-of-Life Chemotherapy Utilization Measure →

Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, and Meropol NJ

March 2019

Manuscript

Journal of Oncology Practice

Flatiron-authored

An evaluation of the impact of missing deaths on overall survival analyses of advanced non–small cell lung cancer patients conducted in an electronic health records database →

Carrigan, G, Whipple, S, Taylor, MD, Torres, AZ, Gossai, A, Arnieri, B, Tucker, M, Hofmeister, PP, Lambert, P, Griffith, SD, Capra, WB

March 2019

Manuscript

Pharmacoepidemiology & Drug Safety

Flatiron-authored

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC) →

El-Deiry WS, Winer A, Slifker M, Taylor S, Adamson BJS, Meropol NJ, Ross EA

March 2019

Manuscript

Frontiers in Oncology

Flatiron-authored

Increased risk of brain metastases in ovarian cancer patients with BRCA mutations →

Ratner E, Bala M, Louie-Gao M, Aydin E, Hazard S, Brastianos PK

March 2019

Manuscript

Gynecologic Oncology

Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practice →

Molife C, Hess LM, Cui ZL, Li XI, Beyrer J, Mahoui M, Oton AB

February 2019

Manuscript

Future Oncology

Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer →

Riaz, F, Presley, CJ, Chiang, AC, Longtine, JA, Soulos, PR, Adelson, KB, Herbst, RS, Nussbaum, NC, Sorg, RA, Abernethy, AP, Agarwala, V, Gross, CP

February 2019

Manuscript

Journal of Geriatric Oncology

Flatiron-authored

Clinical outcomes, treatment patterns, and health resource utilization among metastatic breast cancer patients with germline BRCA1/2 mutation: A real-world retrospective study →

Quek RGW, Mardekian J

January 2019

Manuscript

Advances in Therapy

Treatment patterns and survival outcomes for patients receiving second-line treatment for metastatic colorectal cancer in the USA →

Hess LM, Cui ZL, Mytelka DS, Han Y, Goodloe R, Schelman W

January 2019

Manuscript

International Journal of Colorectal Disease

Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer in the USA →

Li Y, Appius A, Pattipaka T, Feyereislova A, Cassidy A, Ganti AK

January 2019

Manuscript

PLoS One

Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval →

Khozin S, Carson KR, Zhi J, Tucker M, Lee SE, Light DE, Curtis MD, Bralic M, Kaganman I, Gossai A, Hofmeister PP, Torres AZ, Miksad RA, Blumenthal GM, Pazdur R, Abernethy AP

December 2018

Manuscript

The Oncologist

Flatiron-authored

Treatment Patterns, Duration and Outcomes of Pemetrexed Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting →

Winfree KB, Torres AZ, Zhu Y, Muehlenbein C, Aggarwal H, Woods S, Abernethy AP

December 2018

Manuscript

Current Medical Research and Opinion

Flatiron-authored

Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States →

McGrath LJ, Hernandez RK, Overman R, Reams D, Liede A, Brookhart MA, O’Donnell E, Leah J

December 2018

Manuscript

Cancer Medicine

Real-World Anaplastic Lymphoma Kinase (ALK) Rearrangement Testing Patterns, Treatment Sequences, and Survival of ALK Inhibitor-Treated Patients →

Davies J, Martinec M, Coudert M, Delmar P, Crane G

November 2018

Manuscript

Current Medical Research and Opinion

ALK Testing Trends and Patterns Among Community Practices in the United States →

Illei P, Wong W, Wu N, Chu L, Gupta R, Schulze K, Gubens M

October 2018

Manuscript

JCO Precision Oncology

Accelerating Anticancer Drug Development — Opportunities and Trade-offs →

Nass S, Rothenberg M, Pentz R, Hricak H, Abernethy AP, Anderson K, Gee A, Harvey RD, Piantadosi S, Bertagnolli M, Schrag D, Schilsky R

October 2018

Manuscript

Nature Reviews Clinical Oncology

Flatiron-authored

Treatment Patterns and Outcomes for Patients with Advanced Melanoma in US Oncology Clinical Practices →

Whitman E, Liu F, Cao X, Diede SJ, Haiderali A, Abernethy AP

September 2018

Manuscript

Future Medicine

Flatiron-authored

An Observational Study of Concomitant Immunotherapies and Denosumab in Patients with Advanced Melanoma or Lung Cancer →

Liede A, Hernandez RK, Wade S, Bo R, Nussbaum N, Ahern E, Dougall WC, Smyth MJ

September 2018

Manuscript

OncoImmunology

Flatiron-authored

Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Setting →

Presley C, Tang D, Soulos P, Chiang A, Longtine J, Adelson K, Herbst R, Zhu W, Nussbaum N, Sorg R, Agarwala V, Abernethy AP, Gross C

August 2018

Manuscript

JAMA

Flatiron-authored

Patterns of Bisphosphonate Treatment Among Patients with Multiple Myeloma Treated at Oncology Clinics Across the USA: Observations from Real-World Data →

Kim C, Hernandez RK, Cyprien L, Liede A, Cheng P

August 2018

Manuscript

Supportive Care in Cancer

Disparities in the use of programmed death 1 immune checkpoint inhibitors →

O’Connor, JM, Seidl-Rathkopf, K, Torres, AZ, You, P, Carson, KR, Ross, JS, Gross, CP

July 2018

Manuscript

The Oncologist

Flatiron-authored

Comparative Effectiveness from a Single-Arm Trial and Real-World Data: Alectinib versus Ceritinib →

Davies J, Martinec M, Delmar P, Coudert M, Bordogna W, Golding S, Reynaldo M, Crane G

June 2018

Manuscript

Future Medicine

Development and Validation of a High‐Quality Composite Real‐World Mortality Endpoint →

Curtis MD, Griffith S, Tucker M, Taylor M, Capra W, Carrigan G, Holzman B, Torres AZ, You P, Arnieri B, Abernethy AP

May 2018

Manuscript

Health Services Research

Flatiron-authored

Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials →

O’Connor J, Fessele K, Steiner J, Seidl-Rathkopf K, Carson K, Nussbaum N, Yin E, Adelson K, Presley C, Chiang A, Ross J, Abernethy AP, Gross C

May 2018

Manuscript

JAMA Oncology

Flatiron-authored

Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study →

Agarwala V, Khozin S, Singal G, O'Connell C, Kuk D, Li G, Gossai A, Miller V, Abernethy AP

May 2018

Manuscript

Health Affairs

Flatiron-authored

An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer →

Liede A, Wade S, Lethen J, Hernandez RK, Warner D, Abernethy AP, Finelli A

February 2018

Manuscript

Clinical Therapeutics

Flatiron-authored

Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval →

Khozin S, Abernethy AP, Nussbaum N, Zhi J, Curtis MD, Tucker M, Lee S, Light D, Gossai A, Sorg R, Torres AZ, Patel P, Blumenthal G, Pazdur R

January 2018

Manuscript

The Oncologist

Flatiron-authored

Treatment Dynamics of Bone-Targeting Agents Among Men with Bone Metastases from Prostate Cancer in the United States →

Butler A, Cetin K, Hernandez RK, Reams D, Overman R, Kim J, Hirsch B, Abernethy AP, Liede A, Brookhart A

January 2018

Manuscript

Pharmacoepidemiology & Drug Safety

Flatiron-authored

Harnessing the Power of Real-World Evidence (RWE): A Checklist to Ensure Regulatory-Grade Data Quality →

Miksad RA, Abernethy AP

December 2017

Manuscript

Clinical Pharmacology and Therapeutics

Flatiron-authored

Use of Electronic Health Record Data for Quality Reporting →

Abernethy AP, Gippetti J, Parulkar R, Revol C

August 2017

Manuscript

Journal of Oncology Practice

Flatiron-authored

Real-World First-Line Treatment and Overall Survival in Non-Small Cell Lung Cancer Without Known EGFR Mutations or ALK Rearrangements in US Community Oncology Setting →

Abernethy AP, Arunachalam A, Burke T, McKay C, Cao X, Sorg R, Carbone D

June 2017

Manuscript

PLoS One

Flatiron-authored

Treatment Patterns for Advanced Non-Small Cell Lung Cancer After Platinum-Containing Therapy in US Community Oncology Clinical Practice →

McKay C, Burke T, Cao X, Abernethy AP, Carbone D

March 2016

Manuscript

Clinical Lung Cancer

Flatiron-authored

Opportunities and Challenges in Leveraging Electronic Health Record Data in Oncology →

Berger ML, Curtis MD, Smith G, Harnett J, Abernethy AP

March 2016

Manuscript

Future Oncology

Flatiron-authored

Validation of International Classification of Diseases Coding for Bone Metastases in Electronic Health Records Using Technology-Enabled Abstraction →

Liede A, Hernandez RK, Roth M, Calkins G, Larrabee K, Nicacio L

November 2015

Manuscript

Clinical Epidemiology

Flatiron-authored